Safety of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells for Treating Interstitial Cystitis: A Phase I Study

Safety of Human Embryonic Stem Cell-derived Mesenchymal Stem Cells for Treating Interstitial Cystitis: A Phase I Study

There are still no definite treatment modalities for interstitial cystitis (IC). Meanwhile, stem cell therapy is rising as potential alternative for various chronic diseases. This study aimed to investigate the safety of the clinical-grade mesenchymal stem cells (MSCs) derived from human embryonic s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stem cells translational medicine 2022-10, Vol.11 (10), p.1010-1020
Hauptverfasser: Shin, Jung Hyun, Ryu, Chae-Min, Yu, Hwan Yeul, Park, Juhyun, Kang, Ah Reum, Shin, Jeong Min, Hong, Ki-Sung, Kim, Eun Young, Chung, Hyung-Min, Shin, Dong-Myung, Choo, Myung-Soo
Format: Artikel
Sprache:eng
Schlagworte:
Human Clinical
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There are still no definite treatment modalities for interstitial cystitis (IC). Meanwhile, stem cell therapy is rising as potential alternative for various chronic diseases. This study aimed to investigate the safety of the clinical-grade mesenchymal stem cells (MSCs) derived from human embryonic stem cells (hESCs), code name MR-MC-01 (SNU42-MMSCs), in IC patients. Three female IC patients with (1) symptom duration >6 months, (2) visual pain analog scale (VAS) ≥4, and (3) one or two Hunner lesions
ISSN:2157-6564
2157-6580
DOI:10.1093/stcltm/szac065